Mereo BioPharma Group (MREO)
2.31
0.18 (8.45%)
At close: Apr 17, 2025, 3:59 PM
2.32
0.56%
After-hours: Apr 17, 2025, 07:56 PM EDT
8.45% (1D)
| Bid | 2 |
| Market Cap | 357.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -43.25M |
| EPS (ttm) | -0.3 |
| PE Ratio (ttm) | -7.68 |
| Forward PE | -115.25 |
| Analyst | Buy |
| Ask | 2.45 |
| Volume | 2,216,719 |
| Avg. Volume (20D) | 1,342,800 |
| Open | 2.13 |
| Previous Close | 2.13 |
| Day's Range | 2.10 - 2.33 |
| 52-Week Range | 1.57 - 5.02 |
| Beta | 0.65 |
About MREO
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase ...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 24, 2019
Employees 36
Stock Exchange NASDAQ
Ticker Symbol MREO
Website https://www.mereobiopharma.com
Analyst Forecast
According to 7 analyst ratings, the average rating for MREO stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 203.69% from the latest price.
Stock ForecastsNext Earnings Release
Mereo BioPharma Group is scheduled to release its earnings on May 14, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+1.69%
Mereo BioPharma shares are trading higher after JP...
Unlock content with
Pro Subscription
4 months ago
+8.65%
Mereo BioPharma shares are trading higher after Jeffereis initiated coverage on the stock with a Buy rating and $7 price target.
